Population Health Research Institute
Study List

HOPE-TOO (Completed)
Heart Outcomes Prevention Evaluation- The Ongoing Outcomes

 < back
 

The HOPE-2 study evaluated whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus. HOPE-2 was an investigator initiated trial sponsored by the Canadian Institutes of Health Research. At the time of its publication the HOPE-2 trial was the largest trial of homocysteine lowering B vitamins in CVD prevention. The trial findings of no benefit for B vitamin supplementation influenced guidelines and patterns of practice worldwide.

Study Design: Double-Blind, Placebo Control, Randomized, Safety/Efficacy, Parallel Group Desgn

Intervention: Folic Acid, Vitamins B6 and B12 vs. Placebo.

Length of Study: 6.5 years

# of Patients: 5,542

Patient Populations: High-risk chronic stable vascular disease (coronary heart disease, peripheral arterial disease, previous stroke and diabetes with additional risk factor[s]).


Presentations

Extended Vtamin E Results - HTML Slide Set

HOPE-TOO Results

Passive Ramipril Follow-Up Results - HTML Slide Set


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77. Epub 2006 Mar 12.

Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; the HOPE 2 Investigators. Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability. Additional Findings From the HOPE 2 Trial. Stroke. 2009 Feb 19. [Epub ahead of print]

Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E; Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146:761-7. Epub 2007 Apr 30.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca